GCG and type 2 diabetes mellitus: A handful of studies have shown GLP-1 agonists reduce Binge Eating Scale scores in patients with obesity (Richards et al., 2023; Robert et al., 2015) or Type 2 diabetes (Da Porto et al., 2020).